



Q1 2024

Earnings Presentation

Fiscal 2024

Dalrada.com

Company Overview



Dalrada drives innovation that positively impacts people, businesses, and the planet. The company owns and operates a global group of health care, clean energy, precision manufacturing, and technology companies that identify, address, and deliver solutions to economic, environmental, and efficiency problems facing the public, government, and private sectors.



Genefic delivers an exciting core of frontline health products and services that meet the world's demands of today and tomorrow. Dedicated to creating improved health outcomes through redesigned systems and reimagined patient care, **Genefic** offers total health solutions through distinctive offerings.



Dalrada Climate Technology (DCT) is revolutionizing the global clean energy industry through state-of-the-art products—like heat pumps—that help build a sustainable energy future. DCT's unique solutions reduce energy consumption and minimize carbon footprints, increase operational efficiencies, and lower energy costs for clients around the world.



Dalrada Precision Manufacturing (DPM) meets today's critical manufacturing needs and provides high-quality parts and components solutions. Additionally, DPM improves time-to-market capabilities and solves the world's biggest manufacturing and supply chain challenges as a specialized service provider committed to delivering improved efficiencies.



Dalrada Technologies is a proud creator of digital engineering that eclipses standard capabilities. Through next-generation B2B and B2C digital products and services, **Dalrada Technologies** connects the world through cutting-edge software programming, modernized applications, and robust IT products specifically tailored for the digital age.

Product Spotlight:

Dalrada Climate Technology Heat Pump (DCT ONE Series)

State-of-the-art climate technology that combines unrivaled energy efficiency with an extremely low environmental impact.

- ✓ Internationally-recognized heat pump solution that supports global Net Zero initiatives.
- ✓ U.S. General Services Administration & Department of Energy-identified “green building technology.”

The Dalrada’s commercial heat pump is the **only** CO₂-based heat pump that delivers **simultaneous heating and cooling** without combustion or the burning of fossil fuels. It’s the perfect replacement for outdated and inefficient water heaters, steam boilers, chillers, and cooling towers.

Why DCT ONE Series?

- **Long-Term Cost Savings:** lower energy bills through reduced consumption.
- **Increased Energy Efficiency:** advanced technology and climate-agnostic design.
- **Comfort and Convenience:** better temperature control with real-time reporting.
- **Less Environmental Impact:** lower emissions and reduced carbon footprint.
- **Rebates and Incentives:** increased eligibility for reduced overall costs.

Signed, Sealed, (*almost*) Delivered:

Dalrada Climate Technology has secured a backlog of **international contracts** worth approximately **\$900 million**:


- ✓ **2,300**-heat pump contract with JBS Consulting, a Paris-based distributor (5-year contract length).
- ✓ **4,500**-heat pump contract with Crown Glory Holding, a Morocco-based global distributor (7-year contract length).

DECARBONIZING SOLUTIONS

Cost-Effective Heating & Cooling

DCT ONE Series by the Numbers:

- ✓ Up to 7 times more efficient than traditional systems
- ✓ Up to 75% reduced energy consumption
- ✓ Up to 60– 80% energy savings



Subsidiary Spotlight:

Genefic Specialty Pharmacy

Enhanced patient support through prescriptions, medical education, advocacy, and increased transparency.

Genefic Specialty Pharmacy offers a pharmacy experience like no other: a nationally-recognized and certified local pharmacy with a global reach, delivering modern services for a busy world. As a full-service provider, they are redefining personalized healthcare in a way that's educational and transparent for patients and medical staff alike.

In addition to basic pharmacy services, **Genefic Specialty Pharmacy** provides enhanced prescription management, comprehensive and ongoing wellness education, and complete medical assistance for a variety of health conditions.

Expanded Service Offerings:

- Medical condition education
- Diabetes care
- Durable medical equipment (DME)
- Health screenings
- Home delivery
- Immunizations
- Medication therapy
- Wellness classes

Core Values:

- Advocate on behalf of patients
- Facilitate patient education
- Improve patient lives daily
- Create transparency between patients and staff
- Employ highly-trained, ethical pharmacists and technicians



**Redefining
the modern
pharmaceutical
experience.**



Subsidiary Spotlight:

Dalrada Precision Manufacturing

Meeting the critical quality of today's advanced machining and manufacturing needs for global industries.


Dalrada Precision Manufacturing responds to consumer challenges with in-house design, engineering, and distribution through an efficient supply chain and improved time-to-market capabilities.

The subsidiary exceeds the standard of quality of today's advanced products in a variety of industries, including semiconductors, automotive, aviation, biotechnology, pharmaceuticals, and clean energy.

- OEM & custom precision parts
- Clean energy technology & machinery
- Semiconductor & microchip technology
- Industrial-strength cleaners & degreasers

Key Components

- Design and development
- In-house solutions
- Global supply chain
- Engineering excellence



**A total end-to-end
manufacturing
solution delivering
high-quality
components.**

DALRADA
PRECISION MANUFACTURING

Subsidiary Spotlight:

Prakat Solutions

Next-generation digital products and services that connect the world through integrated technological solutions.

Prakat creates a suite of B2B and B2C solutions through a global development team of technology and digital engineering experts.

With hyper-personalized, web 3.0 solutions that eclipse standard digital engineering capabilities, **Prakat** offers advanced software programming, modernized applications, and robust IT products and services specifically tailored for the digital age.

Future-Facing Science

- Software engineering and testing
- Application modernization
- Advanced digital ecosystems
- Digital twinning and machine learning
- Artificial intelligence
- Metaverse and virtual reality


Modern Results

- Better user experiences
- Increased data security
- Improved accuracy
- Safer digital experiences
- Inclusive environments
- Efficient communications

**Digital
engineering that
transcends
traditional
capabilities.**

DALRADA
TECHNOLOGIES

Dalrada Q1 Company Revenue Breakdown



Total:
\$5.0 million

Dalrada's Continued Growth

Q1 | revenue totaled **\$5.0 million** | compared to Q1, ended September 30, 2022
increase of 18% (\$4.3 million)

Q1 2024 OVER Q1 2023 HIGHLIGHTS:



GROSS MARGIN

– 49%

\$0.9 million



SALES, GENERAL, AND ADMINISTRATIVE EXPENSES

+ 24%

\$1.2 million



OPERATING LOSS

+ 72%

\$2.1 million

** \$86 million backlog/potential orders through core segments.



Q1 2024

Financial Highlights



TOTAL COST OF REVENUE:

\$4.0 million



TOTAL CONSOLIDATED
SALES, GENERAL, AND
ADMINISTRATIVE COSTS:

\$6.0 million




TOTAL CONSOLIDATED
LOSS OF OPERATIONS:

\$5.1 million




LOSS PER SHARE (EPS):

\$ - .05



Dalrada Revenue (Fiscal 2021-2024)



Unaudited Consolidated Statements of Operations

	Three Months Ended September 30,	
	2023	2022
Revenues	\$ 4,121,626	\$ 4,172,249
Revenues - related party	896,454	85,518
Total revenues	<u>5,018,080</u>	<u>4,257,767</u>
Cost of revenues	4,047,222	2,356,328
Gross profit	<u>970,858</u>	<u>1,901,439</u>
Operating expenses:		
Selling, general and administrative (includes stock-based compensation of \$1,109,642 and \$467,517, respectively)	6,042,654	4,857,617
Total operating expenses	<u>6,042,654</u>	<u>4,857,617</u>
Loss from operations	<u>(5,071,796)</u>	<u>(2,956,178)</u>
Other income (expense):		
Interest expense	(113,193)	(672,127)
Interest income	19,243	19,069
Other income	334,380	338,077
Gain on expiration of accrued tax liability	—	53,266
Gain (loss) on foreign exchange	(6,770)	47,717
Total other income (expense), net	<u>233,660</u>	<u>(213,998)</u>
Net loss	<u>(4,838,136)</u>	<u>(3,170,176)</u>
Other comprehensive loss		
Foreign currency translation	85,208	63,762
Comprehensive loss	<u>\$ (4,752,928)</u>	<u>\$ (3,106,414)</u>
Net income (loss) attributable to noncontrolling interests	(21,894)	447,613
Net loss attributable to Dalrada Financial Corporation stockholders	<u>\$ (4,816,242)</u>	<u>\$ (3,617,789)</u>
Net loss per common share to Dalrada stockholders - basic	\$ (0.05)	\$ (0.05)
Net loss per common share to Dalrada stockholders - diluted	\$ (0.05)	\$ (0.05)
Weighted average common shares outstanding — basic	<u>89,120,328</u>	<u>72,217,851</u>
Weighted average common shares outstanding — diluted	<u>89,120,328</u>	<u>72,217,851</u>

Safe Harbor

This presentation regarding Dalrada Financial Corporation (“Dalrada”, “DFCO”, “the Company”, “we”, “us”, or “our”) is for you to familiarize yourself with the Company. It contains information, statements, beliefs, and opinions which are forward-looking and which reflect current estimates and expectations for future events, referred to herein and which constitute “forward-looking statements” or “forward-looking information” within the meaning of the Private Securities Litigation Reform Act of 1995.

Statements in this presentation are not historical facts. They may include revenue and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management’s current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance

may differ materially from the above forward-looking statements due to a number of important factors and will be dependent upon a variety of factors including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our products and services in domestic and international markets will continue to expand.

The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company’s expectations regarding these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company’s success are more fully disclosed in the Company’s most recent public filings with the US Securities and Exchange Commission (“SEC”), including its annual report on Form 10-K.

Transformative Innovations.



San Diego Office
600 La Terraza Blvd.
Escondido, CA 92025

Phone: 858.326.2661

Email: investors@dalrada.com

Website: Dalrada.com